Ownership Submission
|
FORM 4
|
|
Check this box if no longer subject to Section 16, Form 4 or Form 5 obligations may continue. See Instruction 1(b).
|
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
OMB APPROVAL
|
|
OMB Number:3235-0287Expires:January 31, 2005Estimated average burden hours per response...0.5
|
|
|
1. Name and Address of Reporting Person *
|
|
Raykov Rosty
|
|
2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [FENC]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
_____ Director
|
_____ 10% Owner
|
|
_____ Officer (give title below)
|
_____ Other (specify below)
|
|
CHIEF EXECUTIVE OFFICER /
|
|
|
(Last)
|
(First)
|
(Middle)
|
|
C/O FENNEC PHARMACEUTICALS, INC. , PO BOX 13628, 68 TW ALEXANDER DRIVE
|
|
3. Date of Earliest Transaction (Month/Day/Year)
|
(Street)
|
|
RESEARCH TRIANGLE PARK
|
NC
|
27709
|
|
4. If Amendment, Date Original Filed(Month/Day/Year)
|
6. Individual or Join/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
|
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
|
|
1.Title of Security
|
2. Transaction Date (Month/Day/Year)
|
2A. Deemed Execution Date, if any (Month/Day/Year)
|
3. Transaction Code
|
4. Securities Acquired (A) or Disposed of (D)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
|
6. Ownership Form: Direct (D) or Indirect (I)
|
7. Nature of Indirect Beneficial Ownership
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
(e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
|
2. Conversion or Exercise Price of Derivative Security
|
3. Transaction Date (Month/Day/Year)
|
3A. Deemed Execution Date, if any (Month/Day/Year)
|
4. Transaction Code
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
|
8. Price of Derivative Security
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
|
11. Nature of Indirect Beneficial Ownership
|
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expriation Date
|
Title
|
Amount or Number of Shares
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
|
Director
|
10% Owner
|
Officer
|
Other
|
Raykov Rosty
C/O FENNEC PHARMACEUTICALS, INC.
PO BOX 13628, 68 TW ALEXANDER DRIVE
RESEARCH TRIANGLE PARK, NC27709
|
|
|
CHIEF EXECUTIVE OFFICER
|
|
Signatures
|
/s/ Rostislav Raykov
|
2024-05-21
|
|
**Signature of Reporting Person
|
Date
|
Explanation of Responses:
|
(*)
|
If the form is filed by more than one reporting person, see Instruction 5(b)(v).
|
|
(**)
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
|
(1)
|
On May 16, 2024, Rostislav Raykov was granted incentive stock options to purchase 200,000 shares of the Issuer's common shares pursuant to the Issuer's 2020 Equity Incentive Plan.
|
|
(2)
|
1/3 of the shares subject to this grant shall vest as of May 16, 2025 (the "Vesting Commencement Date"). 1/24 of the grant shall vest as of the last day of each month following the Vesting Commencement Date. As of April 30, 2027 and thereafter, 100% of the total number of shares subject to this grant shall be vested.
|
|
(3)
|
1. On May 16, 2024, Rostislav Raykov was awarded restricted share units to receive 100,000 shares of the Issuer's common shares pursuant to the Issuer's 2020 Equity Incentive Plan.
|
|
(4)
|
1/3 of the shares subject to this award shall be released from restriction as of May 16, 2025 (the "Vesting Commencement Date"). 1/24 of the award shall be released from restriction as of the last day of each month following the Vesting Commencement Date. As of April 30, 2027 and thereafter, 100% of the total number of shares subject to this award shall be released.
|
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
See Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
